---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000777"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:32:58.903617+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Q1 net loss $39.4M; Phase 3 SMA trial enrollment on track for 2023

## Summary
- Net loss of $39.4M ($0.49 per share) vs $8.0M loss in prior year; revenue $0 vs $33.2M.
- Cash, equivalents & marketable securities $275M as of March 31, 2023, funding into 2025.
- Phase 3 SAPPHIRE trial for apitegromab in SMA enrollment completion expected in 2023, top-line data in 2024.
- Phase 1 DRAGON trial for SRK-181 biomarker and clinical update planned for H2 2023.
- Richard Brudnick appointed to Board of Directors in April 2023.

## SEC filing metadata
- accession: 0001157523-23-000777
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000115752323000777/0001157523-23-000777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000115752323000777/a53395784.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000777
- JSON: https://secwatch.observer/filing/0001157523-23-000777.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000777.txt

## Key facts
- Earnings Releases
  Scholar Rock Holding Corp reported the quarter ended March 31, 2023 results: revenue $0, net income net loss was $39.4 million, EPS $0.49 per share.
  - Period: the quarter ended March 31, 2023
  - Revenue: $0
  - Net income: net loss was $39.4 million
  - EPS: $0.49 per share
  - Result: reported results
  source text: For the quarter ended March 31, 2023, net loss was $39.4 million or $0.49 per share compared to a net loss of $8.0 million or $0.21 per share for the quarter ended March 31, 2022. Revenue was $0 for the quarter ended March 31, 2023, compared to $33.2 million for the quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1727196/000115752323000777/0001157523-23-000777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.